posted on 2012-08-17, 00:00authored byJinghong Kou, Min Song, Abhinandan Pattanayak, Jeong-Eun Lim, Junling Yang, Dongfeng Cao, Ling Li, Ken-ichiro Fukuchi
We evaluated the therapeutic efficacy of combined treatment of Aβ-immunization with
simvastatin in an Alzheimer mouse model at age 22 months. DNA prime-adenovirus boost
immunization induced modest anti-Aβ titers and simvastatin increased the seropositive rate. Aβ-KLH was additionally administered to boost the titers. Irrespective of simvastatin, the immunization did not decrease cerebral Aβ deposits but increased soluble Aβ and tended to exacerbate amyloid angiopathy in the hippocampus. The immunization increased cerebral
invasion of leukocytes and simvastatin counteracted the increase. Thus, modest anti-Aβ titers can increase soluble Aβ and simvastatin may reduce inflammation associated with vaccination in
aged Alzheimer mouse models.
Funding
This research was supported in part by grants from the National Institutes of Health (AG031846, AG031979, AG037814, AG030399, AG029818 and EY018478) and the Alzheimer’s Association (IIRG-07-59494).
History
Publisher Statement
NOTICE: this is the author’s version of a work that was accepted for publication in Journal of Neuroimmunology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Neuroimmunology, [Vol 244, Issue 1-2, (March 2012)] DOI:
doi.org/10.1016/j.jneuroim.2012.01.008